2021
Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy
Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clinical Lung Cancer 2021, 22: 587-595. PMID: 34544620, DOI: 10.1016/j.cllc.2021.08.008.Peer-Reviewed Original ResearchConceptsMolecular risk stratificationAdjuvant chemotherapyDisease-free survivalEGFR mutation statusAdjuvant interventionRisk stratificationEGFR patientsNSCLC patientsEGFR statusMutation statusSmall cell lung cancer patientsNon-squamous NSCLC patientsCell lung cancer patientsStage IA NSCLCStage IB patientsThird-generation TKIsEarly-stage NSCLCNon-Squamous NonLung cancer patientsEarly-stage cohortIB patientsProspective studyResidual diseaseCancer patientsEGFR mutationsMO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy
Woodard G, Kratz J, Haro G, Gubens M, Blakely C, Jones K, Mann M, Jablons D. MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy. Journal Of Thoracic Oncology 2021, 16: s21. DOI: 10.1016/j.jtho.2020.10.061.Peer-Reviewed Original Research
2018
P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy
Woodard G, Wang S, Kratz J, Haro G, Gubens M, Blakely C, Jahan T, Jones K, Mann M, Jablons D. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy. Journal Of Thoracic Oncology 2018, 13: s835. DOI: 10.1016/j.jtho.2018.08.1487.Peer-Reviewed Original ResearchLung adenocarcinoma patientsAdjuvant chemotherapyStage IAAdenocarcinoma patientsChemotherapyPatients
2017
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer
Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2017, 19: 58-64. PMID: 28645632, DOI: 10.1016/j.cllc.2017.05.015.Peer-Reviewed Original ResearchConceptsHigh-risk patientsDisease-free survivalLow-risk patientsAdjuvant chemotherapyNational Comprehensive Cancer Network guidelinesCell lung cancer patientsMolecular profilingEarly-stage NSCLCHigh-risk criteriaLog-rank analysisCell lung cancerHigh-risk designationLung cancer patientsKaplan-Meyer estimatesAdjuvant treatmentNonsquamous NSCLCOccult metastasesStage IAStage NSCLCAdjuvant interventionClinicopathologic characteristicsComplete resectionConsecutive patientsDisease recurrenceNCCN criteria
2015
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas
Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLOS ONE 2015, 10: e0132134. PMID: 26132438, PMCID: PMC4488446, DOI: 10.1371/journal.pone.0132134.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Squamous CellCell MovementChemotherapy, AdjuvantCombined Modality TherapyCyclophosphamideDeoxycytidineDown-RegulationDoxorubicinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleGemcitabineGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLungLung NeoplasmsMaleMiddle AgedNeoplasm ProteinsNeoplasm StagingOrganoplatinum CompoundsPaclitaxelPneumonectomyPrognosisRNA InterferenceRNA, Small InterferingTranscription FactorsVinblastineVinorelbineConceptsLung squamous cell carcinomaSquamous cell carcinomaLung SCC patientsNon-small cell lung cancerLung SCC cellsLung SCC cell linesSCC patientsSCC cell linesAdjuvant chemotherapyCell carcinomaPredictive markerSCC cellsEMX2 expressionImproved overall survivalCurrent staging methodsTissue samplesCell lung cancerNovel prognostic markerAdjacent normal tissuesCell linesOverall survivalSurgical resectionLung cancerPatient outcomesPrognostic marker
2014
Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer
Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2014, 15: 426-432. PMID: 25258195, DOI: 10.1016/j.cllc.2014.07.004.Peer-Reviewed Original ResearchConceptsHigh-risk patientsLow-risk patientsStage IBNCCN criteriaNCCN guidelinesRisk stratificationHigh-risk clinicopathologic featuresEarly-stage NSCLC patientsAdjuvant chemotherapy recommendationsMonths of patientsMolecular risk stratificationCell lung cancerIdentification of patientsSmall cohort studiesMolecular risk assessmentBlinded chart reviewMolecular assaysAdjuvant chemotherapyChemotherapy recommendationsNonsquamous NSCLCStage IAChart reviewCohort studyNSCLC patientsRecurrence outcomes